sterna biologicals announces publication of pre-clinical data in Gastroenterology

Marburg, Germany, 10 October 2016

  • Paper summarizing role of GATA-3 in ulcerative colitis published in Gastroenterology
  • SECURE study of SB012 in patients with moderate to severe ulcerative colitis continues to progress (NCT02129439)

sterna biologicals GmbH & Co. KG ("sterna biologicals") announced today that detailed mechanistic investigations of the role of GATA-3 in ulcerative colitis, performed primarily by Prof Markus Neurath's group in Erlangen (Germany), were published in Gastroenterlogy (Popp et al, 2016).

sterna biologicals announces publication of SB010 Phase IIa results in the New England Journal of Medicine

Marburg, Germany, 17 May 2015

  • SB010 Phase IIa proof-of-concept results published in the New England Journal of Medicine
  • SB010 Phase I programme results published in the Journal of Allergy and Clinical Immunology
  • SB010 development programme comprising four completed clinical trials demonstrates excellent safety profile combined with efficacy comparable to monoclonal antibodies

sterna biologicals co-founder Prof Harald Renz to present key Phase IIa results at ATS

Marburg, Germany, 14 May 2014
sterna biologicals GmbH & Co. KG ("sterna biologicals") announced today that Prof Harald Renz will present key results of the recently completed Phase IIa clinical trial of SB010, an inhaled first-in-class GATA-3 antagonist for the treatment of Th2-driven asthma, at the upcoming American Thoracic Society (ATS) 2014 International Conference being held in San Diego, CA, 16 to 21 March.

sterna biologicals announces DZL to conduct investigator-initiated trial of SB010 in COPD

Marburg, Germany, 3 Sept 2014

  • German Center for Lung Research (DZL) to conduct investigator-initiated trial of SB010 in patients with eosinophilic COPD
  • Further data from Phase IIa trial of SB010 in asthmatic patients to be presented at the European Respiratory Society International Congress 2014 in Munich, Germany

Introducing SB012 for the treatment of ulcerative colitis

Marburg, Germany, 29 April 2014

  • Phase IIa clinical trial of SB012 (the SECURE trial) approved by regulatory agencies

sterna biologicals GmbH & Co. KG ("sterna biologicals") announced today a significant expansion of the company's clinical development pipeline. In addition to SB010 for the treatment of Th2-driven asthma and SB011 for the treatment of atopic dermatitis, SB012 joins these two promising drug candidates as a further GATA-3 antagonist in a major chronic inflammatory indication.